Francesca Wuttke is the CEO and Founder of nen- bringing evicence-based Digital Therapeutics (DTx) pain solutions to preschool kids with cancer. Dr. Wuttke brings broad drug development and healthcare expertise in both the US and Europe, with over 25 years of clinical, commercial, strategic and transactional experience. She has worked with diverse organizations including start-ups, consulting, large and specialty pharma as well as academia. Formerly the Chief Digital Officer of Almirall where she created the Almirall Digital Garden to accelerate and incubate digital health startups. Previously she led European investments as Managing Director for the MSD Global Health InnovationFund, LLC. Prior to that, Dr. Wuttke led Almirall´s Corporate Development Strategy team to transact on both med device and pharma M&A opportunities with a new and targeted focus for the company. Dr. Wuttke worked at Novartis where she was responsible for two Cell and Gene therapy opportunities that were successfully brought into the organization as well as managing the strategy and commercialization for the existing portfolio of cell therapy assets. Dr. Wuttke holds a Ph.D. in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.